Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Diabetes Sci Technol. 2010 Nov 1;4(6):1332-7.

Stabilized glucagon formulation for bihormonal pump use.

Author information

  • 1Biodel Inc., Danbury, Connecticut 06810, USA. ssteiner@biodel.com

Abstract

BACKGROUND:

A promising approach to treat diabetes is the development of an automated bihormonal pump administering glucagon and insulin. A physically and chemically stable glucagon formulation does not currently exist. Our goal is to develop a glucagon formulation that is stable as a clear ungelled solution, free of fibrils at a pH of 7 for at least 7 days at 37 °C.

METHODS:

Experimental glucagon formulations were studied for stability at 25 and 37 °C. Chemical degradation was quantified by reverse phase ultra-performance liquid chromatography. Physical changes were studied using light obscuration and visual observations.

RESULTS:

Glucagon content of Biodel glucagon and Lilly glucagon at pH 2 and pH 4, as measured by high-performance liquid chromatography at 25 °C, was 100% at 7 days compared to 87% and <7%, respectively. Light obscuration measurements indicated Lilly glucagon at pH 4 formed an opaque gel, while Biodel glucagon formulation remained a clear solution beyond 50 days at 37 °C. Visual observations confirmed these results.

CONCLUSIONS:

Biodel glucagon is a stabilized formulation at physiological pH and remains chemically and physically stable beyond 7 days at 37 °C, suggesting its utility for use in a bihormonal pump.

© 2010 Diabetes Technology Society.

PMID:
21129327
[PubMed - indexed for MEDLINE]
PMCID:
PMC3005042
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk